Praxis Precision Medicines Inc (PRAX) - Total Assets
Based on the latest financial reports, Praxis Precision Medicines Inc (PRAX) holds total assets worth $1.39 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Praxis Precision Medicines Inc - Total Assets Trend (2018–2025)
This chart illustrates how Praxis Precision Medicines Inc's total assets have evolved over time, based on quarterly financial data. Also see Praxis Precision Medicines Inc market capitalisation for the company's overall valuation and market capitalisation.
Praxis Precision Medicines Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Praxis Precision Medicines Inc's total assets of $1.39 Billion consist of 65.1% current assets and 34.9% non-current assets. Review PRAX total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 38.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Praxis Precision Medicines Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Praxis Precision Medicines Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Praxis Precision Medicines Inc's current assets represent 65.1% of total assets in 2025, a decrease from 96.5% in 2018.
- Cash Position: Cash and equivalents constituted 38.1% of total assets in 2025, down from 90.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Praxis Precision Medicines Inc Competitors by Total Assets
Key competitors of Praxis Precision Medicines Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Praxis Precision Medicines Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.73 | 6.31 | 12.90 |
| Quick Ratio | 15.73 | 6.31 | 12.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $722.85 Million | $257.97 Million | $294.58 Million |
Praxis Precision Medicines Inc - Advanced Valuation Insights
This section examines the relationship between Praxis Precision Medicines Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.27 |
| Latest Market Cap to Assets Ratio | 9.30 |
| Asset Growth Rate (YoY) | 94.1% |
| Total Assets | $937.91 Million |
| Market Capitalization | $8.72 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Praxis Precision Medicines Inc's assets at a significant premium (9.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Praxis Precision Medicines Inc's assets grew by 94.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Praxis Precision Medicines Inc (2018–2025)
The table below shows the annual total assets of Praxis Precision Medicines Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $937.91 Million | +94.14% |
| 2024-12-31 | $483.11 Million | +449.31% |
| 2023-12-31 | $87.95 Million | -23.61% |
| 2022-12-31 | $115.13 Million | -60.67% |
| 2021-12-31 | $292.75 Million | -3.44% |
| 2020-12-31 | $303.18 Million | +535.67% |
| 2019-12-31 | $47.69 Million | +140.53% |
| 2018-12-31 | $19.83 Million | -- |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more